- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04222855
Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia
Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia: A Randomized Controlled Trial
Both preeclampsia and eclampsia are important health problems, being an important cause of maternal death in the world.
Nifedipine has been used as the drug of choice for the treatment of hypertension during puerperium for more than 25 years.
Diltiazem is an alternative calcium antagonist that is 1000 times less potent than nifedipine.
There are no reports in the literature, no randomized clinical trials that prove the effectiveness of diltiazem for the control of blood pressure in post-partum patients with severe preeclampsia.
Study Overview
Detailed Description
Both preeclampsia and eclampsia are important health problems, being an important cause of maternal death in the world. Although these two pregnancy-related disorders have been widely studied, their cause remains unknown. Pathophysiological mechanism involves the reduction of maternal placental blood flow as of week 20 of gestation, with an increase in peripheral vascular resistance that predominantly takes place in the kidney, liver and brain.
Nifedipine has been used as the drug of choice for the treatment of hypertension during puerperium for more than 25 years. However, there are various studies that report in sensible population the presence of serious adverse effects with the use of this drug, such as cerebral ischemia, myocardial ischemia or tachycardia, as well as episodes of hyper- and hypotension. Consequently, it is necessary to find treatment alternatives for this case.
Diltiazem is an alternative calcium antagonist that is 1000 times less potent than nifedipine, which has the property of producing a selective vasodilatation of arteries beds.
There are no reports in the literature, no randomized clinical trials that prove the effectiveness of diltiazem for the control of blood pressure in post-partum patients with severe preeclampsia.
The objective of this study is to evaluate if diltiazem improves the blood pressure parameters in early puerperium patients with severe preeclampsia.
A researcher who was not involved in the study was performed the randomization by using a random- numbers table and central allocation. All participants and study staff were blind to medication condition. The patients were randomly allocated to one of two groups of treatment: group one was administered 60 mg of diltiazem (tables) while group two (the control) was administered 10 mg of nifedipine (capsule). Both drugs were administered orally every 8 hours. Systolic, diastolic and mean blood pressures and heart rate were recorded and analyzed at baseline and 6, 12, 18, 24, 30, 36, 42 and 48 hours.
A Foley catheter was placed to measure urinary excretion. On the other hand, the blood pressure of all patients was continuously recorded using a monitor (DASH 4000 Dinamar, US) which provided a reading of systolic, diastolic and mean blood pressure trough central venous catheter. The register was taken during the 48-hour observation period, in order to ensure that blood pressure was maintained between 120/70 and 160/110 mmHg; either determine hypotension (which is defined by the pressure at which clinical alterations occur) or hypertension events.
The size of the sample was calculated with the formula of difference between the means of two independent samples. We took the systolic pressure values from a pilot study of 10 subjects for each group. The common standard deviation of delta values (Baseline and after 72-hour pressure difference) is 19 mmHg, a difference between delta values of the treatments is 16.5 mmHg, and a power level of 0.8, resulting in 21 patients per group.
Comparisons between groups on the repeated measures were made using repeated-measure ANOVA. Analyses included fixed effects for time (baseline and 6, 12, 18, 24, 30, 36, 42 and 48 hours) and treatments (diltiazem and nifedipine), and treatments×time interactions. If the interaction was statistically significant, post hoc analysis using the Sidak correction method for mean differences were used to determine whether the changes in levels of arterial blood pressure between the longitudinal assessments were statistically significant between the diltiazem and nifedipine treatments. When necessary, a Greenhouse-Geisser correction was applied to correct for non-sphericity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The following parameters of all patients were within the normal range: hematic biometry, urine and glucose tests, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine, blood coagulation test including prothrombin time and activated partial thromboplastin time. Electrocardiogram and chest radiography showed no pathological data.
Exclusion Criteria:
When the patient falls outside of the aforementioned parameters, or subjects with unstable medical conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diltiazem
Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
|
Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
|
Active Comparator: Nifedipine
Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
|
Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Systolic blood pressure
Time Frame: The register was taken during the 48-hour observation period
|
The register was taken during the 48-hour observation period
|
Diastolic blood pressure
Time Frame: The register was taken during the 48-hour observation period
|
The register was taken during the 48-hour observation period
|
Mean blood pressure
Time Frame: The register was taken during the 48-hour observation period
|
The register was taken during the 48-hour observation period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of hypotension episodes
Time Frame: The counts was taken during the 48-hour observation period
|
The counts was taken during the 48-hour observation period
|
Days of stay in the intensive care unit
Time Frame: The counts was taken during the two-weeks observation period
|
The counts was taken during the two-weeks observation period
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCINSHAE-DGCHFR-HMD-DEI-2008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Preeclampsia
-
Brigham and Women's HospitalCompletedHypertension in Pregnancy | Postpartum | Postpartum Preeclampsia | Gestational Hypertension | Preeclampsia SevereUnited States
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
Columbia UniversityCompletedHypertension | Hypertension, Pregnancy-Induced | Postpartum Preeclampsia | Postpartum Pregnancy-Induced HypertensionUnited States
-
Yale UniversityRecruitingPostpartum Depression | Postpartum Hemorrhage | Patient Empowerment | Patient Education | Postpartum Sepsis | Postpartum Preeclampsia | Postpartum CareUnited States
-
Columbia UniversityRecruiting
-
University of ChicagoRecruiting
-
Washington University School of MedicineRecruitingPreeclampsia Postpartum | Preeclampsia SevereUnited States
-
Weill Medical College of Cornell UniversityNot yet recruitingPostpartum Depression | Postpartum Hemorrhage | Patient Empowerment | Patient Education | Postpartum Sepsis | Postpartum Preeclampsia | Postpartum CareUnited States
-
Hossam Ahmed Abd EllahAssiut UniversityUnknownPostpartum PreeclampsiaEgypt
Clinical Trials on Diltiazem
-
King Saud UniversityUnknown
-
Eisai Inc.Completed
-
Virginia Commonwealth UniversityCompletedAtrial Fibrillation and FlutterUnited States
-
Ventrus Biosciences, IncUnknownAdult Subjects With Anal Fissures.United States
-
S.L.A. Pharma AGCompletedChronic Anal FissureUnited Kingdom, Spain, Bulgaria, Germany, Lithuania, Romania
-
University Hospital, Strasbourg, FranceUnknownIschaemia-reperfusion InjuryFrance
-
Mercy Health MuskegonUnknownAtrial Fibrillation | Atrial Flutter | Rapid Ventricular Response
-
Assiut UniversityUnknownHypotension on Induction
-
Radboud University Medical CenterActive, not recruitingCoronary Vasospasm | Microvascular Angina | Microvascular Ischemia of MyocardiumNetherlands
-
Seoul National University HospitalUnknownAtrial FibrillationKorea, Republic of